52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
May 21 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a clinical trial (pilot study) in Japan for SI-449, an adhesion barrier for use in surgery .
March 23(Reuters) - Seikagaku Corp <4548.T>:Says it announced that the Japanese Ministry of Health, Labour and Welfare has approved the new drug application of HERNICORE® 1.25 units for intradiscal injection in Japan, indicated for the treatment of lumbar disc herniation.
Feb 19 (Reuters) - Seikagaku Corp <4548.T>:Says it will initiate a Phase III clinical trial (additional study) in the U.S. for SI-6603, indicated for the treatment of radicular leg pain (i.e. sciatica) due to a lumbar disc herniation. .
Nov 8 (Reuters) - Ribomic Inc <4591.T>:Says it signed collaborative research contract with SEIKAGAKU CORPORATION <<<4548.T>>>.Says two entities mainly cooperate on new technologies development of drug discovery related to Aptamers.
June 16(Reuters) - Seikagaku Corp <4548.T>:Says it announces the start of phase II study of SI-613 in patients with osteoarthritis of the knee, in the U.S. .
May 12(Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:Says Seikagaku Corp <<<4548.T>>> and Ono Pharmaceutical Co., Ltd. have reached a basic agreement related to.co-development and marketing collaboration on SI-613 under development by Seikagaku for the treatment of osteoarthritis in Japan.
Seikagaku Corp <4548.T> :Says co announces the start of Phase III study of SI-613, a joint improving agent indicated for treatment of osteoarthritis, in Japan.
Seikagaku Corp <4548.T>:Say it signed an agreement with Zimmer Biomet Holdings, Inc. <ZBH.N> to grant Zimmer Biomet Holdings, Inc. the exclusive distribution rights in the U.S. on the joint function improver "VISCO-3TM".
Seikagaku Corporation <4548.T>: Says the co entered into an exclusive worldwide license agreement(excluding Japan) with Ferring Pharmaceuticals for SI-6603(condoliase), a potential treatment for lumbar disc herniation .Says the co will receive an upfront payment of $5 million and milestone payments up to a maximum total amount of $90 million over multiple years upon future progress in development and commercialization.
Seikagaku <4548.T>:Says it signed an agreement for overseas exclusive sale license of lumbar disc herniation treatment agent with Ferring Pharmaceuticals.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.